VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's Disease
Public ClinicalTrials.gov record NCT06874621. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
VY7523-102: A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Multiple Ascending Intravenous Doses of VY7523 in Participants With Early Alzheimer's Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is to be conducted in participants with early Alzheimer's Disease to test VY7523, a new drug being researched for treatment of Alzheimer's Disease. This study will look at how safe the drug is and how it works in the brain. It was first tested in normal, healthy participants who volunteered to participate. The study will look at three different dose levels, starting with the lowest dose first and moving to higher doses and more participants after safety has been reviewed by doctors and researchers. Some patients will receive drug while others will receive placebo. This will help to better compare how the drug works between participants receiving drug and placebo. The study will last up to 6 months for the lower dose groups and 12 months for the highest dose group.
Study identification
- NCT ID
- NCT06874621
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 52 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 50 Years to 90 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 3, 2025 (Actual)
- Primary completion
- Oct 13, 2026 (Actual)
- Completion
- May 2027 (Estimated)
- Last update posted
- Oct 23, 2026
2025 – 2027
United States locations
- U.S. sites
- 19
- U.S. states
- 7
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| VYGR Site 840018 | Los Angeles | California | 90033 | — |
| VYGR Site 840016 | Orange | California | 92866 | — |
| VYGR Site 840022 | San Francisco | California | 94158 | — |
| VYGR Site 840008 | Stamford | Connecticut | 06905 | — |
| VYGR Site 840005 | Delray Beach | Florida | 33445 | — |
| VYGR Site 840021 | Fort Myers | Florida | 33912 | — |
| VYGR Site 840010 | Lady Lake | Florida | 32159 | — |
| VYGR Site 840015 | Miami | Florida | 33126 | — |
| VYGR Site 840014 | Miami | Florida | 33135 | — |
| VYGR Site 840024 | Miami | Florida | 33137 | — |
| VYGR Site 840006 | Orlando | Florida | 32803 | — |
| VYGR Site 840003 | Stuart | Florida | 34997 | — |
| VYGR Site 840004 | The Villages | Florida | 32162 | — |
| VYGR Site 840002 | Wellington | Florida | 33414 | — |
| VYGR Site 840020 | Winter Park | Florida | 32789 | — |
| VYGR Site 840007 | Decatur | Georgia | 30030 | — |
| VYGR Site 840012 | Toms River | New Jersey | 08755 | — |
| VYGR Site 840009 | Matthews | North Carolina | 28105 | — |
| VYGR Site 840011 | Plymouth Meeting | Pennsylvania | 19462 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06874621, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 23, 2026 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06874621 live on ClinicalTrials.gov.